You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 38 No. 2, February 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  BRIEF COMMUNICATIONS AND CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (41)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of an Aldose Reductase Inhibitor on Diabetic Peripheral Neuropathy

Preliminary Report

Antonio Culebras, MD; Jorge Alió, MD; José-Luís Herrera, MD; M. Isabel Pérez López-Fraile, MD

Arch Neurol. 1981;38(2):133-134.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The availability for human experimentation of an inhibitor of the enzyme aldose reductase (alrestatin) affords the opportunity to test the hypothesis that sorbitol intervenes in the development of diabetic peripheral neuropathy.1.2 Furthermore, it provides a potential pharmacologic approach to the prevention of peripheral neuropathy and other complications in diabetes mellitus. In this study, we report the effects of alrestatin on ten patients with diabetic peripheral neuropathy.

METHODS

Ten patients entered the study after their informed consent was obtained. Selected patients were of both sexes, between the ages of 43 and 67 years, and had had diabetes for a mean duration of 14.4 years. On admission to the hospital, they were instructed to continue taking their usual fixed-calorie diet, insulin doses, and oral antidiabetic agents.

Physical examinations and laboratory tests were performed before the study was begun and immediately on its completion. The following battery of laboratory tests was performed: ECG . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Neurology, Upstate Medical Center and Veterans Administration Medical Center, Syracuse, NY (Dr Culebras); and the Fundación Jiménez Díaz, Madrid (Drs Alió, Herrera, and López-Fraile).


Footnotes

Accepted for publication May 26, 1980.

Read in part before the Fourth International Congress on Neuromuscular Diseases, Montreal, Sept 18, 1978.

Reprint requests to Neurology Service (127), Veterans Administration Medical Center, Irving Avenue and University Place, Syracuse, NY 13210 (Dr Culebras).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.